Brandon Capital
Brandon Capital Partners is a Melbourne-based life sciences venture capital firm managing six successive funds totaling over A$700M, investing from seed to expansion stage across Australia, New Zealand, the US, and the UK for institutional LPs and biotech entrepreneurs.
- Company typePrivate
- Founded2006
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Brandon Capital does
Brandon Capital Partners is a Melbourne-headquartered life sciences venture capital firm that manages six successive funds totaling over A$700 million in assets under management. The firm invests across the full life sciences spectrum, from seed-stage ventures through to expansion capital, with a focus on biotechnology, pharmaceuticals, and medical devices. Its portfolio includes companies developing antibody-drug conjugates (Pheon Therapeutics, Myricx Bio), radiopharmaceuticals (AdvanCell), immunotherapies (CatalYm, Pathios Therapeutics), neurodegenerative therapies (NRG Therapeutics, AstronauTx), and respiratory therapeutics (ENA Respiratory), among others. Notable exits include Spinifex Pharmaceuticals (acquired by Novartis for $700M) and Elastagen (acquired by Allergan for up to $120M).
The firm's go-to-market centers on a co-investment model with a concentrated base of Australian institutional Limited Partners, led by superannuation funds HESTA, HostPlus, and StatewideSuper, alongside biotech company CSL and government vehicles including the National Reconstruction Fund Corporation and the Western Australian Government. The firm was originally established through the Medical Research Commercialisation Fund (MRCF) in 2007 and rebranded its incubation platform to Brandon BioCatalyst in March 2022. Brandon BioCatalyst coordinates over 50 Australian and New Zealand research organizations and operates the CUREator national biotech incubator, providing an internal deal-sourcing engine alongside the firm's external investment activity.
Brandon Capital generates revenue through standard VC mechanisms: recurring management fees on committed and invested capital (typically 1.5-2.5% of AUM during the investment period) and performance-based carried interest (typically 20%) on profitable exits above the hurdle rate. Revenue is not publicly disclosed. The firm operates from offices in Melbourne, Sydney, San Francisco, and London, and its Fund VI closed at A$439 million in July 2025, the largest fundraise in its history. Chris Nave serves as Partner, Managing Director, and Co-Founder.
Brandon Capital firmographics
Firmographics- Name
- Brandon Capital
- Legal name
- Brandon Capital Partners
- Website
- https://brandoncapital.vc
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Brandon Capital Partners is a Melbourne-based life sciences venture capital firm managing six successive funds totaling over A$700M, investing from seed to expansion stage across Australia, New Zealand, the US, and the UK for institutional LPs and biotech entrepreneurs.
- Ownership category
- akta.pro rank
Brandon Capital industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment Management
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where Brandon Capital is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Brandon Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Management Fees: VC fund management fees charged on assets under management
- Carried Interest: Performance-based carried interest from successful portfolio company exits, typically 20% of profits above the hurdle rate
Distribution channels1 record
Marketing channels4 records
Brandon Capital product offering
Product offeringCore offering
Brandon Capital Partners is Australasia's leading life sciences venture capital firm that invests in early-stage through expansion-stage biotechnology, medical device, and pharmaceutical companies. The firm manages multiple successive life sciences venture funds (most recently Fund VI at A$439 million) and supports portfolio companies from proof-of-concept through commercialisation via direct equity investment, operational support, and access to its network of over 50 Australian and New Zealand research institutions through the Brandon BioCatalyst program.
Product overview
Brandon Capital Partners is a life sciences venture capital firm that invests in and supports early-stage through expansion-stage life science companies. Rather than offering a product platform, Brandon Capital operates as a capital allocator and investment manager, deploying funds into biotechnology, medical device, and pharmaceutical companies across Australia, New Zealand, the United States, and the United Kingdom. The firm manages multiple investment funds and provides operational support to portfolio companies through its Brandon BioCatalyst initiative, which includes the CUREator national biotech incubator. The firm does not offer a unified software product or technology platform; its offerings consist of venture capital funding, mentorship, and access to a network of research institutions and investors for life sciences entrepreneurs.
Differentiator
Problem solved
Functional benefit
Products and services
- Brandon Capital Fund VI (BB6) Brandon Capital's sixth life sciences venture capital fund providing investment capital from early-stage seed through to expansion stage for Australian and New Zealand life sciences companies. The fund raised A$439 million at final close in July 2025 and is backed by institutional Limited Partners including HESTA, HostPlus, CSL, QIC, NRFC, and the Western Australian Government.
- Brandon BioCatalyst (formerly MRCF) Brandon Capital-managed national life sciences investment collaboration of over 50 organisations including research institutes across Australia and New Zealand. The program supports biotech startups and researchers with funding and commercialisation support, and includes the Biomedical Translation Fund (BTF) programs.
- CUREator National Biotech Incubator National biotech incubator under the Brandon BioCatalyst initiative that supports and accelerates the development of Australian biotech innovations through funding and incubation programs.
Quantifiable outcome
- Spinifex Pharmaceuticals acquired by Novartis for $700 million
- +2 more outcomes
Companies that use Brandon Capital
Customer profileSegments3 records
Ideal customer profiles2 records
Brandon Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Brandon Capital partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CatalYmcoreGerman biotech company with multiple visugromab trials in NSCLC, HCC, and cachexia; Brandon Capital is an investor and active supporter of clinical development program expansion
- Brandon BioCatalyst (formerly MRCF)coreBrandon Capital-managed Medical Research Commercialisation Fund collaboration of over 50 organisations including research institutes across Australia and New Zealand; also includes Biomedical Translation Fund (BTF) programs
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Brandon Capital competitors and assessment
Company assessmentRegional players
- GBS Ventures: Australian life sciences venture capital firm. Regional peer with comparable Australian biotech investment mandate and similar early-to-growth stage focus.
- BioScience Managers: Australian-based life sciences investment manager. Regional peer operating in the same Australasian life sciences ecosystem with overlapping biotech and medtech portfolio exposure.
Direct peers
- OneVentures: Australian venture capital firm with healthcare and biotech specialist funds. Direct peer given its overlapping Australasian life sciences investment mandate and comparable fund sizes.
- IP Group: UK/Australian deep-tech and life sciences VC firm that commercialises university research. Direct peer given its co-investment with Brandon (e.g., Ankere Therapeutics seed round) and similar academic-commercialisation model.
- Uniseed: Australian university-focused venture fund investing in life sciences and deep tech from Australian research institutions. Direct peer with overlapping academic commercialisation deal flow.
Broad incumbents
- Sofinnova Partners: European life sciences VC firm. Comparable given its co-lead role in Myricx Pharma's £4.5M seed alongside Brandon Capital and overlapping ADC/oncology investment focus.
- Novo Holdings (Novo Seeds): Novo Nordisk Foundation's venture arm focused on life sciences. Comparable given its co-lead role in Myricx Bio's $114M Series A alongside Brandon Capital and similar therapeutic focus.
- Forbion: European life sciences venture capital firm with a focused biotech mandate. Comparable as a specialist late-stage life sciences investor operating across similar therapeutic areas to Brandon Capital's portfolio.
- SV Health Investors: Global life sciences-focused VC firm. Comparable as a specialist life sciences investor and active co-investor with Brandon Capital in deals like AdvanCell's $112M Series C and NRG Therapeutics' £50M Series B.
- Abingworth: Global life sciences investment firm. Comparable given its co-lead role in AdvanCell's Series C and shared life sciences venture focus with Brandon Capital.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Brandon Capital social profiles
Digital presenceBrandon Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brandon Capital leadership team
Management profileNumber of profiles
Profiles1 record
Brandon Capital subsidiaries and ownership
Company hierarchySubsidiaries1 record
Brandon Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brandon Capital M&A and investment
M&A and investmentM&A
Investments79 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brandon Capital
What does Brandon Capital do?
Brandon Capital Partners is Australasia's leading life sciences venture capital firm that invests in early-stage through expansion-stage biotechnology, medical device, and pharmaceutical companies. The firm manages multiple successive life sciences venture funds (most recently Fund VI at A$439 million) and supports portfolio companies from proof-of-concept through commercialisation via direct equity investment, operational support, and access to its network of over 50 Australian and New Zealand research institutions through the Brandon BioCatalyst program.
Is Brandon Capital a public or private company?
Brandon Capital is a private company. It is classified as management employee owned and is currently operating.
When was Brandon Capital founded?
Brandon Capital was founded in 2006. It employs 11 to 50 people.
Where is Brandon Capital based?
Brandon Capital is headquartered in Melbourne, Australia, in the Oceania region.
How does Brandon Capital make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.
Who are Brandon Capital's main competitors?
Regional players on record are GBS Ventures and BioScience Managers. Direct peers are OneVentures, IP Group and Uniseed. Broad incumbents are Sofinnova Partners, Novo Holdings (Novo Seeds), Forbion, SV Health Investors and Abingworth.
Does Brandon Capital have an API?
No public API is recorded for Brandon Capital.
What industry is Brandon Capital in?
Brandon Capital's product category is Venture Capital / Life Sciences Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.